- Home
- HCA vs BMY Comparison
HCA vs BMY Comparison
Compare HCA & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | BMY |
|---|---|---|
| Founded | 1968 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5B | 123.7B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCA | BMY |
|---|---|---|
| Price | $481.57 | $58.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 16 |
| Target Price | ★ $528.00 | $62.13 |
| AVG Volume (30 Days) | 822.9K | ★ 9.4M |
| Earning Date | 04-24-2026 | 04-30-2026 |
| Dividend Yield | 0.64% | ★ 4.35% |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 28.33 | N/A |
| Revenue | ★ $75,600,000,000.00 | N/A |
| Revenue This Year | $5.07 | N/A |
| Revenue Next Year | $4.90 | N/A |
| P/E Ratio | $17.29 | ★ $17.26 |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $314.43 | $42.52 |
| 52 Week High | $556.52 | $62.89 |
Technical Indicators
Market Signals| Indicator | HCA | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 49.65 |
| Support Level | $461.11 | $56.45 |
| Resistance Level | $519.90 | $62.39 |
| Average True Range (ATR) | 12.77 | 1.25 |
| MACD | 1.49 | -0.10 |
| Stochastic Oscillator | 45.43 | 34.07 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.